Aquestive Therapeutics, Inc. AQST Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Aquestive Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s free cash flow margin?
- Aquestive Therapeutics, Inc. (AQST) reported free cash flow margin of -88.2% in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s free cash flow margin changed year-over-year?
- Aquestive Therapeutics, Inc.'s free cash flow margin increased by 2.5% year-over-year, from -90.4% to -88.2%.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s free cash flow margin?
- Over 4 years (2020 to 2025), Aquestive Therapeutics, Inc.'s free cash flow margin has grown at a 4.4% compound annual growth rate (CAGR), from -100.3% to -119%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.